FDA Approves Pritelivir for Refractory Mucocutaneous HSV
The FDA has approved pritelivir for refractory mucocutaneous HSV in immunocompromised adults, adding a new antiviral option for a difficult-to-treat population.
Topic
Immunocompromised Patients
Topic